Every three months, the Dengue Vaccine Initiative (DVI) highlights a “Dengue Champion,” calling attention to that person’s contribution to the dengue vaccine research field and their commitment to the fight against dengue fever. Dr.

Dr. Capeding led the first Phase 3 trial ever completed for a dengue vaccine candidate.

Titled, “New chapter unfolding in the fight against dengue with an unwritten ending,” the Dengue Vaccine Initiative’s (DVI) editorial just published in the October issue of Transactions

With the slogan “Immunization for a healthy future. Know, Check, Protect” WHO reminds us this week that vaccines prevent 2-3 million deaths each year. Just imagine this: 2 to 3 million lives. This equals the populations of countries like Mongolia or Botswana.  

In a new editorial published in PLOS NTDs, Sabin Vaccine Institute president Dr.

new study published in Nature Genetics, led by a team of researchers at the Washington University School of Medicine in St. Louis, reveals that the hookworm’s genome has been decoded.

Sabin is happy to announce the arrival of our 2012 Annual Report, featuring highlights from our three programs – Vaccine Advocacy and Education, The Sabin Product Development Partnership, and the Global Network for Neglected Tropical Diseases.

Pages